Table II.

Mortality, mortality after disease, and morbidity according to p53 Arg72Pro genotype in the general population

			Arg/Arg		Arg/Pro			Pro/Pro
Endpoint	Participants	Incidents	Incidence n/10,000 person-yearsa	HR	Incidence n/10,000 person-yearsa	HR (95% CI)	p-value	Incidence n/10,000 person-yearsa	HR (95% CI)	p-value
Mortality	9,219	2,264	270	1.0	238	0.88 (0.81–0.96)	0.005a	210	0.82 (0.68–0.97)	0.02
Mortality after disease
Cancer	2,048	1,074	680	1.0	562	0.87 (0.77–0.98)	0.03	507	0.74 (0.56–0.98)	0.03
Cardiovascular disease	2,849	1,416	560	1.0	498	0.95 (0.85–1.06)	0.36	480	0.85 (0.69–1.05)	0.14
Other	7,429	2,075	197	1.0	173	0.88 (0.81–0.97)	0.007a	148	0.81 (0.68–0.98)	0.03
Morbidity
Cancer	9,218	2,048	170	1.0	178	1.10 (1.01–1.21)	0.03	142	0.91 (0.76–1.10)	0.32
Cardiovascular disease	9,218	2,849	137	1.0	132	0.96 (0.89–1.04)	0.31	128	0.99 (0.86–1.15)	0.93
Other	9,214	7,429	589	1.0	586	0.99 (0.95–1.04)	0.80	607	1.03 (0.94–1.12)	0.55

Hazard ratios were adjusted for gender and age in all analyses. Numbers of participants vary slightly because some participants were excluded because of development of disease before follow-up. International Classification of Diseases 8 and 10 codes are as follows: for cardiovascular disease, 390-458, I00-I99; and for cancer, 140-209, C00-C97. HR, hazard ratio; CI, confidence interval.

^aPerson-years indicates the number of collective years that the individuals in a particular group were observed.

^bRemained statistically significant (P < 0.05) after Bonferroni correction for multiple comparison for two tests on mortality, six tests on mortality after disease, and six tests on morbidity.